July 7, 2023European Journal of Heart Failure66 citationsOpen Access
View Full PaperReal-World Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Heart Failure and Reduced Ejection Fraction: Data from the Swedish Heart Failure Registry
Structured PICO
What is the real-world uptake of SGLT2 inhibitors in patients with heart failure and reduced ejection fraction?
P
Population
Patients with heart failure and reduced ejection fraction (HFrEF) from the Swedish Heart Failure Registry
I
Intervention
Sodium-glucose cotransporter 2 inhibitors (SGLT2i)
O
Outcome
Real-world use and uptake of SGLT2i
Real-world uptake of SGLT2 inhibitors in HFrEF patients has been rapid, increasing three-fold over 2 years, though further efforts are needed to ensure equitable implementation.
Abstract
Use of SGLT2i increased three-fold over 2 years. Although this indicates a more rapid translation of trial results and guidelines into clinical practice compared to previous HF drugs, further efforts are advocated to complete the implementation process while avoiding inequities across different patient subgroups and discontinuations.